• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ABCG2 Gene Record

  • Summary
  • Interactions
  • Claims
  • ABCG2 9429 Druggable Genome

    Alternate Names:

    9429
    ATP BINDING CASSETTE SUBFAMILY G MEMBER 2 (JUNIOR BLOOD GROUP)
    ABCG2
    ABC15
    ABCP
    BCRP
    BCRP1
    BMDP
    CD338
    CDw338
    EST157481
    GOUT1
    MRX
    MXR
    MXR-1
    MXR1
    UAQTL1
    603756
    74
    ENSG00000118777
    OTTHUMG00000130601
    Q9UNQ0
    ABCG2_HUMAN
    ATP-BINDING CASSETTE, SUB-FAMILY G, MEMBER 2 (PLACENTA-SPECIFIC ATP- BINDING CASSETTE TRANSPORTER) (BREAST CANCER RESISTANCE PROTEIN) (MITOXANTRONE RESISTANCE ASSOCIATED PROTEIN). [SOURCE:UNIPROT/SWISSPROT;ACC:Q9UNQ0]
    PA390
    ATP-binding cassette transporter G2
    T56556
    ATP-binding cassette sub-family G member 2

    Gene Info:

    Target Subclass ABCG
    Target Subclass Active_transporters
    Target Main Class Transporters
    Transmembrane Helix Count 5
    Human Readable Name DRUGGABLE GENOME
    Gene Biotype PROTEIN_CODING
    (6 More Sources)

    Gene Categories: Category Details

    TRANSPORTER
    ABC TRANSPORTER
    DRUGGABLE GENOME

    Publications:

    Gupta et al., 2007, Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)., J Pharm Sci
    Marchetti et al., 2008, Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice., Mol. Cancer Ther.
    Bauer F et al., 2010, Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor., Bioorg Med Chem
    Robey et al., 2001, Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells., Clin. Cancer Res.
    Zembruski NC et al., 2011, Interaction potential of etravirine with drug transporters assessed in vitro., Antimicrob Agents Chemother
    Ghodke Y et al., 2012, PharmGKB summary: zidovudine pathway., Pharmacogenet Genomics
    Kobayashi H et al., 2015, Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer., Clin Lung Cancer
    Lemos C et al., 2011, Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients., Pharmacogenomics
    Akasaka K et al., 2010, Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer., Cancer Chemother Pharmacol
    Cusatis G et al., 2006, Pharmacogenetics of ABCG2 and adverse reactions to gefitinib., J Natl Cancer Inst
    Breedveld et al., 2005, The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients., Cancer Res.
    Verboom MC et al., 2019, Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors., Pharmacogenomics J
    Skoglund K et al., 2014, Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line., Pharmacogenet Genomics
    Delord M et al., 2013, High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients., Oncotarget
    Petain A et al., 2008, Population pharmacokinetics and pharmacogenetics of imatinib in children and adults., Clin Cancer Res
    Ozvegy-Laczka et al., 2004, High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter., Mol. Pharmacol.
    Wang et al., 2007, Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2., Drug Metab. Dispos.
    Allegra S et al., 2017, Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients., Pharmacogenomics
    Allegra S et al., 2016, Deferasirox AUC efficacy cutoff and role of pharmacogenetics., Eur J Clin Pharmacol
    Cusato J et al., 2016, Role of pharmacogenetics on deferasirox AUC and efficacy., Pharmacogenomics
    Sánchez Martín A et al., 2013, Impact of pharmacogenetics on CNS side effects related to efavirenz., Pharmacogenomics
    Winter E et al., 2014, Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones., J Med Chem
    Xiao G et al., 2012, Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates., Drug Metab Dispos
    Winter E et al., 2013, Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2., J Med Chem
    Tsuchiya K et al., 2017, High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants., Pharmacogenet Genomics
    Kashihara Y et al., 2017, Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP., J Pharm Sci
    Gotanda K et al., 2015, Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene., Br J Clin Pharmacol
    Wiese MD et al., 2014, Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis., Pharmacogenomics J
    Yamasaki Y et al., 2008, Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans., Clin Pharmacol Ther
    Allen JD et al., 2002, A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance., Cancer Res
    Lee CA et al., 2015, Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design., Drug Metab Dispos
    Juvale K et al., 2013, Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2., Eur J Med Chem
    Zhang et al., 2004, Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport., Pharm. Res.
    Zhao J et al., 2014, Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer., Med Oncol
    McLeod HL et al., 2010, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741., J Clin Oncol
    Oshiro C et al., 2009, Taxane pathway., Pharmacogenet Genomics
    Pawarode et al., 2007, Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins., Cancer Chemother. Pharmacol.
    Lee et al., 2005, Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein., J. Pharmacol. Exp. Ther.
    De Mattia E et al., 2013, Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment., Pharmacogenet Genomics
    Kajita et al., 2006, Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats., J. Pharm. Pharmacol.
    Combes S et al., 2011, Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2., J Med Chem
    Chu YH et al., 2015, Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma., PLoS One
    Narjoz C et al., 2015, Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients., Invest New Drugs
    Kim HR et al., 2013, Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients., Cancer Chemother Pharmacol
    Han JY et al., 2009, Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer., Lung Cancer
    Ueshima S et al., 2018, Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation., Br J Clin Pharmacol
    Ueshima S et al., 2017, Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation., Pharmacogenet Genomics
    Kendra KL et al., 2015, A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors., Mol Cancer Ther
    Keskitalo JE et al., 2009, Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin., Pharmacogenomics
    Allegra S et al., 2018, Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations., J Clin Pharmacol
    Ho et al., 2007, Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants., Pharmacogenet. Genomics
    Birmingham BK et al., 2015, Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States., Eur J Clin Pharmacol
    Lee HK et al., 2013, Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients., Pharmacogenomics
    Chasman DI et al., 2012, Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial., Circ Cardiovasc Genet
    Hu M et al., 2010, Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients., Pharmacogenet Genomics
    Bailey KM et al., 2010, Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study., Circ Cardiovasc Genet
    Tomlinson B et al., 2010, ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin., Clin Pharmacol Ther
    Kitamura S et al., 2008, Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin., Drug Metab Dispos
    Zhang W et al., 2006, Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males., Clin Chim Acta
    Keskitalo JE et al., 2009, ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin., Clin Pharmacol Ther
    Li XQ et al., 2015, Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives., Eur J Med Chem
    Ishiguro N et al., 2013, Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods., Drug Metab Dispos
    Brackman DJ et al., 2019, Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol., Clin Pharmacol Ther
    Wright DFB et al., 2018, The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool., Br J Clin Pharmacol
    Roberts RL et al., 2017, ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout., Pharmacogenomics J
    Pick A et al., 2008, Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2)., Bioorg Med Chem
    Baxi SM et al., 2018, Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV., Pharmacogenomics J
    Klarica Domjanović I et al., 2018, Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy., Br J Clin Pharmacol
    Shen CH et al., 2016, Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy., Epilepsy Res
    Zhou Y et al., 2015, Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients., Drug Metab Pharmacokinet
    Stacy AE et al., 2013, Molecular pharmacology of ABCG2 and its role in chemoresistance., Mol Pharmacol
    Wang et al., 2008, Antipsychotic drugs inhibit the function of breast cancer resistance protein., Basic Clin. Pharmacol. Toxicol.
    Roberts JK et al., 2016, Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant., Drug Metab Dispos
    Tsamandouras N et al., 2014, Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach., Clin Pharmacol Ther
    Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
    Jenko B et al., 2017, Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis., Pharmacogenomics J
    Jabeen S et al., 2015, Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate., Pharmacogenomics J
    Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics
    Stamp LK et al., 2010, Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate., Pharmacogenet Genomics
    Warren RB et al., 2008, Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis., J Invest Dermatol
    Nakagawa H et al., 2008, Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2., Biochem J
  • CHEMBL488910   ABCG2

    Interaction Score: 3.99

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24611893 22266779 24304387


    Sources:
    DTC

  • CHEMBL428402   ABCG2

    Interaction Score: 1.99

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18678495


    Sources:
    DTC

  • RETUSIN   ABCG2

    Interaction Score: 1.99

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23851114


    Sources:
    DTC

  • ELACRIDAR   ABCG2

    Interaction Score: 1.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22266779


    Sources:
    DTC PharmGKB

  • CHEMBL444075   ABCG2

    Interaction Score: 1.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26197160


    Sources:
    DTC

  • APIXABAN   ABCG2

    Interaction Score: 1.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29457840 28678049


    Sources:
    PharmGKB

  • TARIQUIDAR   ABCG2

    Interaction Score: 1.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20621487


    Sources:
    DTC

  • ROSUVASTATIN   ABCG2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28322941 25630984 23930675 22331829 20679960 20207952 20130569 18617601 16784736 19474787


    Sources:
    PharmGKB

  • SILYBIN A   ABCG2

    Interaction Score: 0.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15290869


    Sources:
    NCI

  • ETRAVIRINE   ABCG2

    Interaction Score: 0.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21189339


    Sources:
    DTC

  • DOLUTEGRAVIR   ABCG2

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28858994


    Sources:
    PharmGKB

  • DELAVIRDINE   ABCG2

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21189339


    Sources:
    DTC

  • DEFERASIROX   ABCG2

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28346059 27193993 27043265


    Sources:
    PharmGKB

  • VORICONAZOLE   ABCG2

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17518356


    Sources:
    NCI

  • SULFASALAZINE   ABCG2

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28322941 25872459 24394199 18167504


    Sources:
    PharmGKB TTD

  • PRAZOSIN   ABCG2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23073734


    Sources:
    DTC

  • ITRACONAZOLE   ABCG2

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17518356


    Sources:
    NCI

  • EFAVIRENZ   ABCG2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21189339 23859571


    Sources:
    DTC PharmGKB

  • NILOTINIB   ABCG2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24322003


    Sources:
    PharmGKB

  • NITROFURANTOIN   ABCG2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17093006


    Sources:
    NCI

  • TENOFOVIR   ABCG2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28462920


    Sources:
    PharmGKB

  • CEFTRIAXONE   ABCG2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29873816


    Sources:
    PharmGKB

  • LAMOTRIGINE   ABCG2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791014 27610747 26213157


    Sources:
    PharmGKB

  • LEUCOVORIN   ABCG2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24338217 24018773 20530282


    Sources:
    PharmGKB

  • ALLOPURINOL   ABCG2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30924126 29341237 26810134


    Sources:
    PharmGKB

  • TOPOTECAN   ABCG2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27052877


    Sources:
    PharmGKB

  • IMATINIB   ABCG2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15805252 30713339 24322003 24123600 18981009 15155841


    Sources:
    NCI PharmGKB

  • PRAVASTATIN   ABCG2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17622941 19842935


    Sources:
    NCI PharmGKB

  • PRASTERONE   ABCG2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15448171


    Sources:
    NCI

  • ALVOCIDIB   ABCG2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11205902


    Sources:
    NCI

  • KETOCONAZOLE   ABCG2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17518356


    Sources:
    NCI

  • SUNITINIB   ABCG2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26244574 25344452 24013576


    Sources:
    PharmGKB

  • CYCLOSPORINE   ABCG2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16805961 21488686 17031644


    Sources:
    DTC NCI PharmGKB

  • CHLORPROMAZINE   ABCG2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18834354


    Sources:
    NCI

  • FLUVASTATIN   ABCG2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19842935


    Sources:
    PharmGKB

  • NEVIRAPINE   ABCG2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21189339


    Sources:
    DTC

  • CAPECITABINE   ABCG2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24338217 20530282


    Sources:
    PharmGKB

  • OXALIPLATIN   ABCG2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24338217 20530282


    Sources:
    PharmGKB

  • METHOTREXATE   ABCG2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011 27217051 25778468 21317831 20386493 18256692 18237272


    Sources:
    PharmGKB

  • GEFITINIB   ABCG2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25554506 21332310 20035425 17148776


    Sources:
    PharmGKB

  • ZIDOVUDINE   ABCG2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22960662


    Sources:
    PharmGKB

  • TACROLIMUS   ABCG2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17031644


    Sources:
    NCI

  • IRINOTECAN   ABCG2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24018773 18221820


    Sources:
    PharmGKB

  • SIMVASTATIN   ABCG2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24598718 19842935


    Sources:
    PharmGKB

  • PAZOPANIB   ABCG2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25504632


    Sources:
    PharmGKB

  • ERLOTINIB   ABCG2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18723475


    Sources:
    NCI

  • GENISTEIN   ABCG2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15290869


    Sources:
    NCI

  • LAMIVUDINE   ABCG2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   ABCG2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24338217 24018773 20530282


    Sources:
    PharmGKB

  • 7-ETHYL-10-HYDROXYCAMPTOTHECIN   ABCG2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIROLIMUS   ABCG2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17031644


    Sources:
    NCI

  • ATORVASTATIN   ABCG2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19474787


    Sources:
    PharmGKB

  • DAUNORUBICIN   ABCG2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24021215


    Sources:
    PharmGKB

  • RUCAPARIB   ABCG2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DASATINIB   ABCG2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24322003


    Sources:
    PharmGKB

  • CURCUMIN   ABCG2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25587128


    Sources:
    PharmGKB

  • DOCETAXEL   ABCG2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21151855


    Sources:
    PharmGKB

  • MITOXANTRONE   ABCG2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • DOXORUBICIN   ABCG2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11956086


    Sources:
    PharmGKB

  • PACLITAXEL   ABCG2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21151855


    Sources:
    PharmGKB

  • CYCLOPHOSPHAMIDE   ABCG2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • GEMCITABINE   ABCG2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Ensembl: ENSG00000118777

    • Version: 101_38

    Alternate Names:
    ABCG2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TEND: Q9UNQ0

    • Version: 01-August-2011

    Alternate Names:
    ENSG00000118777 Ensembl Gene Id
    ABCG2_HUMAN Uniprot Id
    ABCG2 Gene Symbol

    Gene Info:
    Target Subclass ABCG
    Target Subclass Active_transporters
    Target Main Class Transporters

    Publications:

  • RussLampel: ENSG00000118777

    • Version: 26-July-2011

    Alternate Names:
    ABCG2 Display Id
    ATP-BINDING CASSETTE, SUB-FAMILY G, MEMBER 2 (PLACENTA-SPECIFIC ATP- BINDING CASSETTE TRANSPORTER) (BREAST CANCER RESISTANCE PROTEIN) (MITOXANTRONE RESISTANCE ASSOCIATED PROTEIN). [SOURCE:UNIPROT/SWISSPROT;ACC:Q9UNQ0] Description
    ENSG00000118777 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • PharmGKB: ABCG2

    • Version: 18-August-2020

    Alternate Names:
    PA390 PharmGKB ID

    Gene Info:

    Publications:
    Tsuchiya K et al., 2017, High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants., Pharmacogenet Genomics
    Narjoz C et al., 2015, Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients., Invest New Drugs
    Chu YH et al., 2015, Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma., PLoS One

  • NCI: ABCG2

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Gupta et al., 2007, Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)., J Pharm Sci
    Marchetti et al., 2008, Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice., Mol. Cancer Ther.
    Lee et al., 2005, Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein., J. Pharmacol. Exp. Ther.

  • DTC: ABCG2

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Xiao G et al., 2012, Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates., Drug Metab Dispos
    Zembruski NC et al., 2011, Interaction potential of etravirine with drug transporters assessed in vitro., Antimicrob Agents Chemother
    Ishiguro N et al., 2013, Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods., Drug Metab Dispos

  • HingoraniCasas: ENSG00000118777

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000118777 Gene Symbol
    ABCG2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • GO: ABCG2

    • Version: 01-February-2022

    Alternate Names:
    ABCP GO Gene Synonym
    BCRP GO Gene Synonym
    BCRP1 GO Gene Synonym

    Gene Info:

    Gene Categories:
    ABC TRANSPORTER

    Publications:

  • TTD: ATP-binding cassette transporter G2

    • Version: 2020.06.01

    Alternate Names:
    ABCG2 TTD Gene Abbreviation
    T56556 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: ABCG2

    • Version: 01-February-2022

    Alternate Names:
    ATP-binding cassette sub-family G member 2 Gene Name
    Q9UNQ0 UniProt ID

    Gene Info:

    Gene Categories:
    TRANSPORTER

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21